Initial Statement of Beneficial Ownership (3)
15 Januar 2020 - 11:26PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Broadfin Healthcare Master Fund Ltd |
2. Date of Event Requiring Statement (MM/DD/YYYY)
1/9/2020
|
3. Issuer Name and Ticker or Trading Symbol
NOVELION THERAPEUTICS INC. [NVLNF]
|
(Last)
(First)
(Middle)
20 GENESIS CLOSE, ANSBACHER HOUSE, SECOND FLOOR, P.O. BOX 1344 |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director ___X___ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Street)
GRAND CAYMAN, E9 KY1-1108
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Shares | 2541222 | D (1) | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Warrants | (2) | (2) | COMMON SHARES | (2) | (2) | D (1) | |
Explanation of Responses: |
(1) | The securities are held in the account of Broadfin Healthcare Master Fund, Ltd., a private investment fund managed by Broadfin Capital, LLC and may be deemed to be beneficially owned by Kevin Kotler, managing member of Broadfin Capital, LLC. Each of Broadfin Capital, LLC, Broadfin Healthcare Master Fund, Ltd. and Kevin Kotler (collectively, the "Reporting Persons") disclaim beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and affirmatively disclaim being a "group" for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"). |
(2) | Broadfin Healthcare Master Fund, Ltd. owns 909,296 warrants with a strike price of $4.40 which expire on 3/16/2022. The warrants may not be converted if, after such conversion, the Reporting Person would beneficially own, as determined in accordance with Section 13(d) of the Act, more than 9.99% of the Common Shares outstanding immediately after giving effect to such conversion. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Broadfin Healthcare Master Fund Ltd 20 GENESIS CLOSE, ANSBACHER HOUSE SECOND FLOOR, P.O. BOX 1344 GRAND CAYMAN, E9 KY1-1108 |
| X |
|
|
Broadfin Capital, LLC 300 PARK AVENUE, 25TH FLOOR NEW YORK, NY 10022 |
| X |
|
|
KOTLER KEVIN C/O BROADFIN CAPITAL, LLC 300 PARK AVENUE, 25TH FLOOR NEW YORK, NY 10022 |
| X |
|
|
Signatures
|
BROADFIN HEALTHCARE MASTER FUND, LTD., By: /s/ Kevin Kotler, Director | | 1/15/2020 |
**Signature of Reporting Person | Date |
BROADFIN CAPITAL, LLC, By: /s/ Kevin Kotler, Managing Member | | 1/15/2020 |
**Signature of Reporting Person | Date |
/s/ Kevin Kotler | | 1/15/2020 |
**Signature of Reporting Person | Date |
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
Echtzeit-Nachrichten über Novelion Therapeutics Inc (NASDAQ): 0 Nachrichtenartikel
Weitere Novelion Therapeutics Inc. News-Artikel